← Back to all trials
Recruiting
NCT07704840
A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)
Conditions: Post-Stroke Spasticity
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 42
Sponsor: Alberto Esquenazi
Location: Jeffersi=on Moss Magee Rehabilitation Elkins Park Pennsylvania
Summary
The goal of this clinical trial is to learn if the drug BMS-986368 works to treat post stroke spasticity in adults who have had a stroke. BMS-986368 is a designed to increase natural compounds in the body that may help calm nerves that cause muscles to be tight or spasm. The study will also learn about the safety of drug BMS-986368
Eligibility Criteria
Inclusion Criteria:
* Ischemic or hemorrhagic stroke diagnosis 4 to 18 months prior to enrollment.
* History of post stroke spasticity for at least 2 months prior to Screening Visit.
* Modified Ashworth Scale (mAS) score ≥2 and \
Source: ClinicalTrials.gov (NCT07704840). StuddyBuddy aggregates publicly available trial information.
